MITF and melanoma: In another report linking dedifferentiation of melanoma cells with acquired resistance to targeted therapy and inflammatory signaling from immunotherapy, the degree of dedifferentiation (upregulation of NGFR and downregulation of MITF) was associated with cell sensitivity to ferroptosis, suggesting that a ferroptosis-inducing drug could be a co-treatment component reducing the dedifferentiation-based resistance [47].